Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
1993-9-8
|
pubmed:abstractText |
Malignant lymphoma of the skin is a type of extranodal lymphoma, in which the main organ involved is the skin, and 80-90% of cases in Japan show a T-cell phenotype. Mycosis fungoides (MF) and Sézary syndrome (SS) are common T-cell lymphomas of the skin with a benign prognosis. Therefore, various forms of topical therapy, such as topical steroid, photochemotherapy (PUVA) and interferons, have been indicated for the low-risk group (stages I A, I B and II A), whereas electron-beam irradiation, retinoid plus interferon (IFN), photopheresis and deoxycoformycin (DCF) plus IFN have been indicated for intermediate-risk group (stages II B and III). The cutaneous involvement of B-cell lymphoma has been considered an unmistakable sign of progression and dissemination of lymphoid disease, and is thus associated with a poor prognosis. However, some primary cutaneous B-cell lymphomas (CBCLs) show a benign prognosis, and electron-beam irradiation has been indicated for early-stage CBCL (stages I and II). However, the prognosis of high-risk group CTCL (stage IV) and cutaneous B-cell lymphoma (CBCL) (stages III and IV) is poor. Therefore, an effective multiagent combination chemotherapy, such as MACOP-B, M-BACOD or ProMACE-Cyta BOM is required for patients with advanced-stage CTCL and CBCL. With regard to age at the time of the first medical examination, patients with CTCL or CBCL at an advanced stage have a tendency to be older. Therefore, a mild but effective therapy, such as DCF plus IFN is recommendable.
|
pubmed:language |
jpn
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Bleomycin,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Leucovorin,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisolone,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0385-0684
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
20
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1308-13
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:7688500-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:7688500-Bleomycin,
pubmed-meshheading:7688500-Chemotherapy, Adjuvant,
pubmed-meshheading:7688500-Combined Modality Therapy,
pubmed-meshheading:7688500-Cyclophosphamide,
pubmed-meshheading:7688500-Doxorubicin,
pubmed-meshheading:7688500-Humans,
pubmed-meshheading:7688500-Leucovorin,
pubmed-meshheading:7688500-Lymphoma, B-Cell,
pubmed-meshheading:7688500-Lymphoma, T-Cell,
pubmed-meshheading:7688500-Methotrexate,
pubmed-meshheading:7688500-PUVA Therapy,
pubmed-meshheading:7688500-Prednisolone,
pubmed-meshheading:7688500-Prednisone,
pubmed-meshheading:7688500-Skin Neoplasms,
pubmed-meshheading:7688500-Vincristine
|
pubmed:year |
1993
|
pubmed:articleTitle |
[Lymphomas of the skin].
|
pubmed:affiliation |
Dept. of Dermatology, Yokohama City University School of Medicine.
|
pubmed:publicationType |
Journal Article,
English Abstract
|